Richtlijn Diabetische nefropathie (2006) - Kwaliteitskoepel

B e h a n d e l i n gConclusieNiveau 1Naast het gunstige effect op de preventie en behandeling van nierfunctieverlieshebben antihypertensiva bij mensen met diabetesmellitus gunstige effecten op de cardiovasculaire morbiditeit, en op decardiovasculaire en totale mortaliteit. Het blijft heel belangrijk om debloeddruk afdoende te verlagen.A2: Curb 1996 25 , Birkenhager 2000 26 , Hansson 1998 27 , Hansson 1999 28 ,Tatti 19989 29 , Hansson 1999 30 , HOPE 2000 31 , Lindholm 2002 32 , ALLHAT2001 33 , Wing 2003 34 , UKPDS 1998 35A1: Turnbull 2003 37 (zij het niet alleen betrekking hebbend op DM)Literatuur1. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascularoutcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy.Lancet 2000;355:253-9.2. Hovind P, Rossing P, Tarnow L, et al. Progression of diabetic nephropathy. Kidney Int 2001;59:702-9.3. United Kingdom Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular andmicrovascular complications in type 2 diabetes: (UKPDS 38). BMJ 1998;317:703-13.4. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.The Collaborative Study Group. N Engl J Med 1993;329:1456-62.5. Kasiske BL, Kalil RS, Ma JZ, et al. Effect of antihypertensive therapy on the kidney in patients with diabetes: a metaregressionanalysis. Ann Intern Med 1993;118:129-38.6. Strippoli GF, Craig M, Schena FP, et al. Antihypertensive agents for primary prevention of diabetic nephropathy.J Am Soc Nephrol 2005;16:3081-91.7. Gansevoort RT, Apperloo AJ, Heeg JE, et al. The antiproteinuric effect of antihypertensive agents in diabeticnephropathy. Arch Intern Med 1992;152:2137-40.8. Rossing P, Hommel E, Smidt UM, et al. Reduction in albuminuria predicts diminished progression in diabeticnephropathy. Kidney Int 1994;45:S145-9.9. ALLHAT officers and coordinators. Major outcomes in high-risk hypertensive patients randomized to angiotensinconvertingenzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002;288:2981-97.10. Mann JFE, Gerstein HC, Pogue J, et al. Renal insufficiency as a predictor of cardiovascular outcomes and theimpact of ramipril; the HOPE randomised trial. Ann Intern Med 2001;134:629-36.11. Mathiesen ER, Hommel E, Giese J, et al. Efficacy of captopril in postponing nephropathy in normotensive insulindependent diabetic patients with microalbuminuria. BMJ 1991;303:81-7.12. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes andnormoalbuminuria or microalbuminuria. The EUCLID study group. Lancet 1997;349:1787-92.13. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabeticnephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.14. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartanin patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.59